A multicentre study of coagulation and haemostatic variables during oral contraception: variations with four formulations

BJOG: An International Journal of Obstetrics & Gynaecology

Volumn 98, Issue 11, 1991, Pages 1117-1128

 

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; LEVONORGESTREL; NORETHISTERONE ACETATE;

ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ANTIGENS; ANTIPLASMIN; ANTITHROMBINS; BLOOD COAGULATION; CONTRACEPTIVES, ORAL, COMBINED; DOUBLE-BLIND METHOD; FACTOR VII; FACTOR X; FEMALE; FIBRINOGEN; FIBRINOLYSIS; HUMAN; PLATELET COUNT;

EID: 0025936490     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.1991.tb15364.x     Document Type: Article

References (32)

1. The coagulation mechanism in oral contraception
2. The hypercoagulability states
3. Low fibrinolytic activity of veins during trcatmcnt with cthinyl ocstrodiol
4. Effect of female hor‐mones used as oral contraceptives in the fibrino‐lytic system in the blood
5. Factor VII in an industrial population
6. Anti‐thrombin iii and the oestrogen content of com‐bined oestro‐progestogen contraccptives
7. Increased activity of vitamin K dependent clotting factors in human hyperli‐poproteinaemia
8. Oral contraception and blood coagulability
9. Hae‐mostatic variables associated with diabetes and its complications
10. Effects of combined oestrogen‐progestogen oral contracep‐tives. oestrogen and progestogen on antiplasmin and antithrombin activities
11. Effect of a progestin estrogen oral contraceptive on blood clotting factors
12. Investigations of deaths from pulmonary coronary and cerehral thrombosis and embolism in women of childbear‐ing age
13. Thromboembolic disease and the steroid content of oral contraccptives. A report to the Committee on Safety of Drugs
14. Increased cuglobulin fibrinolytic potential in women on oral contraccp‐tives low in ocstrogen‐levels of extrinsic and intrinsic plasminogen activators. prekallikrein. factor XII and C, inactivator
15. An epi‐demiological study of the haemostatic and other effects of oral contraccptives
16. Progestogens and cardiovascular reactions associ‐ated with oral contraccptives and a comparison of safety of 5Oand 30μg ocstrogen preparations
17. Oral contraceptives, clotting factors and thrombosis
18. Epidemiology of atheroma, thrombosis and ischaemic heart disease
19. The haemostatic mechanism in oral contraception
20. Design & analysis of randomised clinical trials requiring prolonged observation of each patient. I: Introduction & Design. II: Analysis & Examples
21. Thrombosis and factor VII activity
22. Oral contraceptives, blood clotting and thrombosis
23. Oral contraception and thromboembolic diseases
24. Hemostatic system changes induced by 50 μg and 30 μg estrogen/progestogen oral contraceptives
25. Thromboembolism and oral contraceptives: an epidemiological case control study
26. Differences in coagulation and haemostatic parameters in normal women of childbearing age from different ethnic groups and geographical locations
27. Oral contraceptive hormones and blood coagulability
28. Investigation of relation between use of oral contraceptives and thromboembolic disease
29. Investigation of relation between use of oral contraceptives and thromboembolic disease. A further report
30. Mortality among oral contraceptive users: 20 year follow‐up of women in a cohort study